FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington,      | D.C. 2054 | 19 |
|------------------|-----------|----|
| rvasiliiliqibii, | D.C. 2034 | +3 |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL             |  |  |  |  |  |  |  |  |
|--------------------------|--|--|--|--|--|--|--|--|
| OMB Number: 3235-0287    |  |  |  |  |  |  |  |  |
| Estimated average burden |  |  |  |  |  |  |  |  |
| hours per response:      |  |  |  |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person*     Steinhart Richard I     |  |                            |                 |   | 2. Issuer Name and Ticker or Trading Symbol BioXcel Therapeutics, Inc. [ BTAI ] |  |                  |   |                 |   |                         |  | heck all app<br>Direct                                      | licable)<br>tor                                     | ng Per  | son(s) to Iss | vner   |   |
|---|--|----------------------------|-----------------|---|---|--|------------------|---|-----------------|---|-------------------------|--|---|---|---|---------------|--|---|
| (Last)  | (Last) (First) (Middle) C/O BIOXCEL THERAPEUTICS, INC. |                            |                 | 3. Date of Earliest Transaction (Month/Day/Year) 05/14/2023 |   |  |                  |   |                 |   |                         | ^ below  | r (give title<br>r)<br>Chief Fina                           | ncial   | Other (s<br>below)<br>Officer   | specify       |  |   |
| 555 LONG WHARF DRIVE, 12TH FLOOR                                  |  |                            |                 | 4. If a   | 4. If Amendment, Date of Original Filed (Month/Day/Year)                        |  |                  |   |                 |   |                         |  | 6. Individual or Joint/Group Filing (Check Applicable Line) |   |   |               |  |   |
| (Street)  | AVEN C   | Γ                          | 06511           | L   | -   | X Form filed by One Reporting Person  Form filed by More than One Reporting  Person  |                  |   |                 |   |                         |  |   |   |   |               |  |   |
| (City)  | (S   | tate)                      | Zip)            |   | Ru  | Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Ir |                  |   |                 |   |                         | rsuant to a c  |   |   |   |               |  |   |
|   |  | Tabl                       | e I - I         | Non-Deriv   | ative   | Sec  | uriti            | ies A   | cquire          | d, D  | isposed (               | of, or E   | Beneficia   | lly Owne  | ed  |               |  |   |
| 1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Y |  | Year) i                    | Execution Date, |   | Date,   | Transaction Disposed C   |                  | es Acquired (A) or<br>Of (D) (Instr. 3, 4 and 5)                    |                 | 5. Amount of Securities Beneficially Owned Following Reported |                         | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4)                              | n: Direct<br>or Indirect<br>nstr. 4)                        | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership |   |               |  |   |
|   |  |                            |                 |   |   |  |                  |   | Code            | v   | Amount                  | (A) or<br>(D)  | Price   | Transa  | action(s)<br>3 and 4)   |               |  | (Instr. 4)                              |
| Common Stock 05/14/20   |  | 23                         | 3               |   |   | M  |                  | 5,000   | A               | (1)   | 6,500                   |  |   | D   |   |               |  |   |
| Common  | Common Stock 05/15/20                                  |                            | 23              | 3   |   |  | S <sup>(2)</sup> |   | 5,000           | D   | \$27.172                | 7 <sup>(3)</sup> 1   | 1,500   |   | D   |               |  |   |
|   |  | Ta                         | ble I           | II - Deriva<br>(e.g., p                                     |   |  |                  |   |                 |   | sposed of<br>, converti |  |   | y Owned   | I   |               |  |   |
| Derivative Conversion Dat   |  | Date (Month/Day/Year) Exec |                 | eemed<br>ution Date,<br>th/Day/Year)                        |   | Transaction<br>Code (Instr.  |                  | ivative<br>urities<br>juired<br>or<br>posed<br>D)<br>tr. 3, 4<br>5) | Expiration Date |   |                         | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative Securi<br>(Instr. 3 and 4) |   | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4) | ly            | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | Beneficial<br>Ownership<br>t (Instr. 4) |
|   |  |                            |                 |   | Code  | v  | (A)              | (D)   | Date<br>Exercis | able  | Expiration<br>Date      | Title  | Amount<br>or<br>Number<br>of<br>Shares                      |   |   |               |  |   |
| Restricted<br>Stock   | (1)  | 05/14/2023                 |                 |   | M   |  |                  | 5,000   | (4)             |   | (4)                     | Common   | 5,000   | \$0   | 0   |               | D  |   |

## **Explanation of Responses:**

- $1. \ Restricted \ Stock \ Unit \ ("RSU") \ represents \ a \ contingent \ right \ to \ receive \ one \ share \ of \ the \ Issuer's \ Common \ Stock \ a \ contingent \ right \ to \ receive \ one \ share \ of \ the \ Issuer's \ Common \ Stock \ a \ contingent \ right \ to \ receive \ one \ share \ of \ the \ Issuer's \ Common \ Stock \ a \ contingent \ right \ to \ receive \ one \ share \ of \ the \ Issuer's \ Common \ Stock \ a \ contingent \ right \ to \ receive \ one \ share \ of \ the \ Issuer's \ Common \ Stock \ a \ contingent \ right \ to \ receive \ one \ share \ of \ the \ Issuer's \ Common \ Stock \ a \ contingent \ right \ to \ receive \ one \ share \ of \ the \ Issuer's \ Common \ Stock \ a \ contingent \ right \ right \ a \ contingent \ right \$
- 2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 23, 2022.
- 3. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from \$26.84 to \$27.63. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- $4.\ On\ May\ 14,\ 2022,\ the\ Reporting\ Person\ was\ granted\ 5,000\ RSUs\ that\ vested\ and\ settled\ on\ May\ 14,\ 2023.$

/s/ Richard Steinhart

05/16/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.